Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in patients with congestive heart failure (CHF) and/or hyponatremia (HYP)

被引：0
|
作者：
Van Wart, SA [1 ]
Cirincione, BB [1 ]
Ludwig, EA [1 ]
Chen, X [1 ]
Shoaf, S [1 ]
Grasela, TH [1 ]
Mallikaarjun, S [1 ]
机构：
[1] Cognigen Corp, Otsuka Maryland Res Inst, Buffalo, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P1 / P1
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure
    Poder, P
    Eha, J
    Sundberg, S
    Antila, S
    Heinpalu, M
    Loogna, I
    Planken, Ü
    Rantanen, S
    Lehtonen, L
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2003, 41 (08) : 365 - 373
  • [32] Pharmacokinetic(PK)/pharmacodynamic(PD) evaluation of CHF 2819.01 (novel cholinesterase inhibitor) in patients with probable Alzheimer's disease.
    Jhee, SS
    Fabbri, L
    Zarotsky, V
    Piccinno, A
    Rosenthal, M
    Moran, SV
    Ereshefsky, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P66 - P66
  • [33] Use of Tolvaptan in Patients With Hyponatremia Due to Heart Failure: Initial Experience
    Rodriguez-de Munoz, Ydelise M.
    Sanchez-Lazaro, Ignacio J.
    Almenar-Bonet, Luis
    Martinez-Dolz, Luis
    Rodriguez-Serrano, Maria
    Salvador-Sanz, Antonio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2013, 66 (04): : 319 - 321
  • [34] Emergency department experience with tolvaptan in patients with acute heart failure and hyponatremia
    Llorens, Pere
    Lau-Cheng, Arturo
    Manuel Carratala, Jose
    Climent, Eduardo
    EMERGENCIAS, 2012, 24 (02): : 126 - 129
  • [35] EVALUATION OF IRON STATUS IN PATIENTS WITH CONGESTIVE HEART FAILURE (CHF)
    Barbullushi, A.
    Refatllari, E.
    Bulo, A.
    Godo, A.
    Korita, I
    Heta, N.
    Beqja, A.
    Daja, P.
    Goda, A.
    Banushi, A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S460 - S460
  • [36] Serological markers in congestive heart failure (CHF) patients.
    Printzen, G
    Moor, BK
    Mohacsi, P
    Hess, O
    Wermuth, B
    CLINICAL CHEMISTRY, 2002, 48 (06) : A149 - A149
  • [37] A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip
    Sung, Jong Hwan
    Kam, Carrie
    Shuler, Michael L.
    LAB ON A CHIP, 2010, 10 (04) : 446 - 455
  • [38] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF RAMIPRIL IN PATIENTS WITH CONGESTIVE HEART-FAILURE (NYHA-III-IV)
    GERCKENS, U
    GRUBE, E
    MENGDEN, T
    SIGEL, H
    WAGNER, WL
    LAHN, T
    IRMISCH, R
    METZGER, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 13 : S49 - S51
  • [39] Development of a pharmacokinetic-pharmacodynamic (PK/PD) model for carvedilol and the prediction of β1-blockade in patients with congestive heart failure administered immediate-release (IR) and controlled-release (CR) carvedilol.
    Tenero, David
    Henderson, Linda
    Campanile, Andrea
    Baidoo, Charlotte
    Danoff, Theodore
    Boyle, Duane
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1067 - 1067
  • [40] Good response to tolvaptan shortens hospitalization in patients with congestive heart failure
    Kogure, Tomohito
    Jujo, Kentaro
    Hamada, Kazuyuki
    Saito, Katsumi
    Hagiwara, Nobuhisa
    HEART AND VESSELS, 2018, 33 (04) : 374 - 383
12345